Payment overview · 2025
General Payments
$318.82
19 reported records · 11 companies
Healthcare provider profile · identity verified
Sean Patrick Callahan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OAK HARBOR, OH · NPI 1194811828
Verified facts
What the public records show
CMS Open Payments records show Sean Patrick Callahan, M.D. received $318.82 in general payments during 2025 across 19 reported records.
Lilly USA, LLC accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Rexulti, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $99.16 | 31.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.95 | 11.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.88 | 10.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.39 | 8.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.54 | 7.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.39 | 6.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.54 | 6.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.64 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.82 | 5.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.37 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.14 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.82 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $69.21 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.77 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.77 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.88 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.39 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 95 |
| Furosemide | Furosemide | 323 | 78 |
| Potassium Chloride | Potassium Chloride | 309 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 58 |
| Simvastatin | Simvastatin | 275 | 58 |
| Metformin Hcl | Metformin Hcl | 260 | 60 |
| Lisinopril | Lisinopril | 253 | 63 |
| Gabapentin | Gabapentin | 242 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 58 |
| Omeprazole | Omeprazole | 234 | 54 |
| Eliquis | Apixaban | 213 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 39 |
| Montelukast Sodium | Montelukast Sodium | 148 | 42 |
| Diclofenac Sodium Er | Diclofenac Sodium | 147 | 51 |
| Alprazolam | Alprazolam | 144 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 31 |
| Meloxicam | Meloxicam | 123 | 30 |
| Tramadol Hcl | Tramadol Hcl | 122 | 29 |
| Spironolactone | Spironolactone | 116 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 33 |
| Carvedilol | Carvedilol | 95 | 23 |
| Ezetimibe | Ezetimibe | 95 | 25 |
| Allopurinol | Allopurinol | 93 | 18 |
| Memantine Hcl | Memantine Hcl | 91 | 15 |
| Xarelto | Rivaroxaban | 91 | 11 |
| Losartan Potassium | Losartan Potassium | 90 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 24 |
| Donepezil Hcl | Donepezil Hcl | 87 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 13 |
| Alendronate Sodium | Alendronate Sodium | 80 | 20 |
| Celecoxib | Celecoxib | 80 | 20 |
| Buspirone Hcl | Buspirone Hcl | 78 | 20 |
| Trazodone Hcl | Trazodone Hcl | 73 | 14 |
| Divalproex Sodium | Divalproex Sodium | 71 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 18 |
| Lorazepam | Lorazepam | 70 | 16 |
| Bupropion Xl | Bupropion Hcl | 69 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 69 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 12 |
| Mirtazapine | Mirtazapine | 63 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 14 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 19 |
| Lactulose | Lactulose | 57 | suppressed |
| Bumetanide | Bumetanide | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Jardiance | Empagliflozin | 53 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 13 |
| Atenolol | Atenolol | 49 | 12 |
| Nystatin | Nystatin | 48 | 19 |
| Azithromycin | Azithromycin | 47 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Tradjenta | Linagliptin | 46 | suppressed |
| Cefdinir | Cefdinir | 44 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 40 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Famotidine | Famotidine | 38 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 25 |
| Prednisone | Prednisone | 36 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 13 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 16 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Niacin Er | Niacin | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 14 |
| Mometasone Furoate | Mometasone Furoate | 22 | 16 |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Mupirocin | Mupirocin | 14 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.82 · 19 records | Lilly USA, LLC | AIRSUPRA, AREXVY, Auvelity, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, REXULTI, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error